EE346 Comparison of Diagnosis, Administration, and Treatment-Related Cost of Targeted Radiopharmaceutical Therapies in Patients With Metastatic Castration-Resistant Prostate Cancer (MCRPC) From a Third-Party Payer Perspective
Abstract
Authors
A Ruppert K Bassett J Luong S Chen B Patel A Robson